QT Prolongation and Cardiac Risk

Overview

Erythromycin prolongs the QT interval on electrocardiogram by blocking cardiac potassium channels responsible for ventricular repolarization. This prolongs the action potential duration and creates electrical heterogeneity in the ventricles, predisposing to torsades de pointes (TdP) — a potentially fatal polymorphic ventricular tachycardia.

While absolute risk remains low (<0.1% for TdP in general populations), the widespread use of erythromycin and potential for catastrophic outcomes necessitates understanding risk factors, monitoring strategies, and mitigation approaches.

QT Interval: Electrophysiology Basics

What Is the QT Interval?

The QT interval represents the time from ventricular depolarization (QRS complex) to complete ventricular repolarization (end of T wave). It reflects the total duration of ventricular electrical activity.

Normal values (heart rate-corrected, QTc):

• Males: <450 milliseconds (ms)
• Females: <460 ms (longer due to hormonal effects on ion channels)
• Borderline prolongation: 450–470 ms (males), 460–480 ms (females)
• Prolonged: >470 ms (males), >480 ms (females)
• High risk: >500 ms regardless of sex

Heart Rate Correction

The QT interval varies inversely with heart rate (longer at slow rates, shorter at fast rates). To standardize measurement, the QT interval is corrected for heart rate using formulas:

• Bazett formula (most common): QTc = QT / √RR interval
• Fridericia formula (more accurate at extremes of HR): QTc = QT / ∛RR interval

Most modern ECG machines calculate QTc automatically, though manual verification is recommended for critical decisions.

Phases of Ventricular Action Potential

Understanding the cellular basis of the QT interval clarifies how drugs like erythromycin affect repolarization:

• Phase 0 (depolarization): Rapid sodium influx (QRS complex)
• Phase 1 (early repolarization): Transient outward potassium current
• Phase 2 (plateau): Calcium influx balanced by potassium efflux (ST segment)
• Phase 3 (repolarization): Delayed rectifier potassium currents (IKr, IKs) restore negative membrane potential (T wave)
• Phase 4 (resting): Maintenance of resting potential

Critical point: The rapid delayed rectifier current (IKr) is the primary target of erythromycin, encoded by the hERG gene.

Mechanism: hERG Channel Blockade

The hERG Potassium Channel

The human ether-à-go-go-related gene (hERG, also known as KCNH2) encodes the alpha subunit of the cardiac potassium channel responsible for the rapid delayed rectifier current (IKr). This current is essential for phase 3 repolarization — the downstroke of the cardiac action potential corresponding to the T wave.

How Erythromycin Blocks hERG

Erythromycin and other macrolides block hERG channels through direct binding within the channel pore. The proposed mechanism involves:

• Binding site: Inner cavity of the channel pore, accessible when the channel is in the open or inactivated state
• Molecular interaction: Erythromycin's large lactone ring and positively charged desosamine sugar interact with aromatic amino acid residues (Tyr652, Phe656) lining the pore
• Channel state preference: Preferential binding to inactivated channels ("trapping" phenomenon)
• Result: Reduced IKr current → delayed phase 3 repolarization → prolonged action potential duration → prolonged QT interval

Concentration-Dependence

hERG blockade is concentration-dependent:

• IC50 (concentration producing 50% inhibition): ~20–80 μM for erythromycin (varies by study methodology)
• Therapeutic plasma concentrations: 0.5–2 μg/mL (~0.7–2.7 μM)
• Implication: Therapeutic doses produce modest hERG inhibition (~5–15%), but this increases significantly with:
  • High doses (especially IV ≥4 g/day)
  • Accumulation in renal/hepatic impairment
  • Drug interactions increasing erythromycin levels

Why Prolongation Causes Arrhythmias

QT prolongation alone does not directly cause arrhythmias. Rather, it creates electrical vulnerability through:

• Dispersion of repolarization: Different regions of myocardium repolarize at different times, creating electrical gradients
• Early afterdepolarizations (EADs): During prolonged phase 2/3, calcium channels can reopen, triggering premature beats
• Triggered activity: EADs initiate torsades de pointes when they occur in electrically heterogeneous myocardium
• Reentry circuits: Electrical dispersion creates functional reentry pathways sustaining polymorphic VT

Torsades de Pointes

Definition and Recognition

Torsades de pointes ("twisting of the points" in French) is a polymorphic ventricular tachycardia characterized by:

• Rapid ventricular rate (150–250 bpm)
• QRS axis that appears to "twist" around the baseline (amplitude waxes and wanes)
• Preceded by prolonged QT interval and pause-dependent initiation
• May spontaneously terminate (causing syncope) or degenerate into ventricular fibrillation (sudden cardiac death)

Epidemiology with Erythromycin

Absolute risk:

• General population: <0.1% (very rare with oral therapy)
• Intravenous erythromycin: 0.1–1% (higher risk, especially with rapid infusion)
• High-risk patients (see below): 1–5%

Epidemiological data:

• Case reports and pharmacovigilance data: >100 cases of erythromycin-associated TdP reported to FDA
• Most cases involve multiple risk factors (IV route, electrolyte abnormalities, drug interactions)
• Median time to onset: 3–7 days (range: hours to weeks)
• Mortality: ~10–15% if TdP degenerates to VF; higher if cardiac arrest occurs outside hospital

Clinical Presentation

• Palpitations: Sensation of rapid, irregular heartbeat
• Dizziness, lightheadedness: From transient hypoperfusion
• Syncope: Loss of consciousness if TdP sustained >10–15 seconds
• Seizure-like activity: May occur with cerebral hypoperfusion
• Sudden cardiac arrest: If TdP degenerates to ventricular fibrillation
• Asymptomatic QT prolongation: Many patients have no symptoms until arrhythmia occurs

Risk Factors for QT Prolongation and Torsades

Risk is cumulative — each additional factor exponentially increases probability of TdP.

Patient-Specific Factors

Drug-Related Factors

High-Risk Concomitant QT-Prolonging Drugs

These drugs should generally be avoided with erythromycin:

• Class IA antiarrhythmics: Quinidine, procainamide, disopyramide
• Class III antiarrhythmics: Amiodarone, sotalol, dofetilide, ibutilide, dronedarone
• Antipsychotics: Haloperidol, chlorpromazine, thioridazine, ziprasidone, droperidol
• Other antibiotics: Fluoroquinolones (moxifloxacin, levofloxacin), azithromycin (lower risk than erythromycin)
• Antifungals: Fluconazole (high dose), pentamidine
• Antiemetics: Ondansetron (especially IV >16 mg), droperidol
• Methadone: Dose-dependent QT prolongation
• Antihistamines (older): Terfenadine, astemizole (withdrawn in most countries)

For comprehensive drug interaction management, see the drug interactions page.

Risk Stratification Protocol

Low-Risk Patients (Routine Care)

Criteria (ALL must be met):

• Oral erythromycin formulation
• No structural heart disease
• Baseline QTc <450 ms (males) or <460 ms (females)
• Normal electrolytes (K+ >3.5, Mg2+ >1.5)
• No concomitant QT-prolonging drugs
• No history of arrhythmias or syncope
• Age <65 years

Management:

• No baseline ECG required
• Standard patient education on palpitations/syncope
• Instruct to report cardiac symptoms

Moderate-Risk Patients (Enhanced Monitoring)

Criteria (ANY present):

• Age ≥65 years
• Female sex with borderline QTc (460–480 ms)
• Mild structural heart disease (e.g., controlled hypertension with LVH)
• One minor risk factor (e.g., well-controlled hypothyroidism)
• Short-course IV erythromycin (<3 days) with normal baseline

Management:

• Obtain baseline ECG and electrolytes
• Correct electrolyte abnormalities before starting
• Review medication list for QT-prolonging drugs
• Patient counseling on symptoms (palpitations, dizziness, syncope)
• Consider repeat ECG if symptoms develop

High-Risk Patients (Intensive Monitoring or Avoidance)

Criteria (ANY present):

• Baseline QTc >480 ms or prior torsades de pointes
• Congenital long QT syndrome (contraindicated)
• Multiple risk factors (e.g., elderly female with hypokalemia)
• Concurrent QT-prolonging antiarrhythmic
• Recent MI or unstable coronary syndrome
• Advanced heart failure (NYHA III-IV)
• Severe electrolyte disturbance (K+ <3.0, Mg2+ <1.2)
• IV erythromycin >3 days or high-dose (>4 g/day)

Management:

• Consider alternative antibiotic (azithromycin, fluoroquinolone if not QT-prolonging, beta-lactam)
• If erythromycin essential:
  • Baseline ECG and electrolytes
  • Correct K+ to >4.0 mEq/L, Mg2+ to >2.0 mg/dL before initiating
  • Discontinue other QT-prolonging drugs if possible
  • Telemetry monitoring (especially first 3–5 days)
  • Repeat ECG at 2–3 days and with any symptoms
  • Discontinue if QTc >500 ms or ΔQTc >60 ms from baseline
  • Cardiology consultation for complex cases

ECG Monitoring and Interpretation

When to Obtain Baseline ECG

• All patients receiving IV erythromycin
• Any patient with ≥1 risk factor (see above)
• Prolonged therapy (>14 days)
• Uncertain cardiac history

QT Interval Measurement Technique

1. Use lead II or V5 (most prominent T waves)
2. Measure from QRS onset to T wave end (return to isoelectric baseline)
3. Average ≥3 consecutive beats (especially if irregular rhythm)
4. Calculate heart rate from RR interval
5. Apply correction formula (Bazett or Fridericia)
6. Compare to sex-specific thresholds

Pitfalls:

• U waves: Do not include in QT measurement (separate from T wave)
• Atrial fibrillation: Average 5–10 beats; use Fridericia formula
• Bundle branch block: QT naturally prolonged; use caution interpreting
• Automated measurements: Often inaccurate; verify manually for critical decisions

Monitoring Schedule During Therapy

Electrolyte Monitoring

• Baseline: Serum potassium, magnesium, calcium in all patients with risk factors
• During therapy: Repeat every 3–5 days if:
  • Diuretic use (especially loop or thiazide diuretics)
  • GI losses (diarrhea, vomiting)
  • Renal impairment
  • IV erythromycin
• Target levels: K+ ≥4.0 mEq/L, Mg2+ ≥2.0 mg/dL (higher than "normal" lower limit to maximize repolarization reserve)

Clinical Management of QT Prolongation

Prevention Strategies

1. Patient selection: Avoid erythromycin in high-risk patients; choose alternative
2. Electrolyte optimization: Correct hypokalemia/hypomagnesemia before starting
3. Drug reconciliation: Eliminate or minimize QT-prolonging drugs
4. Route selection: Use oral formulation when possible
5. Infusion rate (IV): Infuse over ≥60 minutes (never bolus)
6. Lowest effective dose: Avoid unnecessary high doses (>4 g/day)
7. Shortest duration: Limit therapy to minimum effective course

If QTc Becomes Prolonged During Therapy

Management of Torsades de Pointes

Acute treatment (requires ACLS-trained personnel):

1. Unstable patient (no pulse, unresponsive):
   • Immediate unsynchronized defibrillation (200 J biphasic, then 300 J, then 360 J)
   • CPR and ACLS protocols
   • IV magnesium sulfate 2 g over 1–2 minutes (even if Mg2+ normal)
2. Stable patient (conscious, pulsatile):
   • IV magnesium sulfate: 2 g over 5–10 minutes, then infusion 1–2 g/hour
   • Correct electrolytes: Replete K+ to 4.5–5.0 mEq/L
   • Discontinue all QT-prolonging drugs
   • Increase heart rate (shortens QT):
     • Temporary pacing at 90–110 bpm (most effective)
     • Isoproterenol infusion 2–10 mcg/min if pacing unavailable
   • Continuous ECG monitoring
3. Cardiology/electrophysiology consultation for refractory cases

Do NOT use:

• Class IA or III antiarrhythmics (will worsen QT prolongation)
• Amiodarone (paradoxically can worsen drug-induced TdP)
• Synchronized cardioversion (TdP is polymorphic; synchronization ineffective)

Alternative Antibiotics in High-Risk Patients

When erythromycin poses unacceptable cardiac risk, consider these alternatives based on indication:

For Respiratory Infections

• Azithromycin: Lower QT risk than erythromycin (still has some risk; use cautiously)
• Doxycycline: No QT effect; excellent atypical coverage
• Amoxicillin-clavulanate: For typical pathogens
• Respiratory fluoroquinolones: Avoid moxifloxacin (QT effect); levofloxacin has lower risk

For Skin/Soft Tissue Infections

• Clindamycin: Excellent gram-positive coverage; no QT effect
• Cephalexin: First-generation cephalosporin; no QT effect
• Doxycycline: For MRSA, atypicals

For Chlamydia (Pregnancy)

• Azithromycin: Preferred (also Category B; better tolerated)
• Amoxicillin: Alternative (lower cure rate ~80–85%)

For Pertussis

• Azithromycin: Equivalent efficacy; 5-day course
• Trimethoprim-sulfamethoxazole: Second-line alternative

QT Risk: Macrolide Comparison

Clinical pearl: While azithromycin has the lowest QT risk among macrolides, a 2012 FDA warning highlighted increased cardiovascular mortality in a large observational study. However, absolute risk remains very low, and azithromycin is generally preferred over erythromycin when cardiac risk is a concern.

Special Populations

Elderly Patients (≥65 Years)

• Baseline QT tends to be longer
• Higher prevalence of structural heart disease
• Polypharmacy increases drug interaction risk
• Lower threshold for obtaining baseline ECG
• Consider dose reduction if hepatic/renal impairment

Patients with Heart Failure

• Electrical remodeling prolongs baseline QT
• Diuretic use → electrolyte depletion
• Often on QT-prolonging drugs (amiodarone, dofetilide)
• Recommendation: Use alternative antibiotic; if erythromycin essential, intensive monitoring

ICU/Critically Ill Patients

• Multiple risk factors often present (electrolyte disturbances, sedatives, organ dysfunction)
• IV erythromycin common
• Telemetry usually available
• Protocol: Daily ECG, twice-daily electrolytes, cardiology consultation for QTc >480 ms

Patient Counseling

What to Tell Patients

For all patients on erythromycin:

• "Erythromycin can rarely affect your heart's electrical system, causing an abnormal heart rhythm."
• "Stop taking erythromycin and seek immediate medical attention if you experience:
  • Rapid or irregular heartbeat (palpitations)
  • Dizziness or fainting
  • Chest pain or shortness of breath
• "Tell me about all other medications you take, including over-the-counter drugs and supplements."

For high-risk patients:

• "Due to your medical history [specify: heart condition, other medications, etc.], you have a higher risk of heart rhythm problems with this antibiotic."
• "We will monitor your heart with ECG tests during treatment."
• "It's very important to maintain your potassium and magnesium levels; take any supplements prescribed."
• "If you feel your heart racing or feel faint, call 911 immediately."

Related Topics